Published in Cancer Res on January 01, 1983
Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. J Exp Med (2011) 1.27
Numerical analysis of etoposide induced DNA breaks. PLoS One (2009) 1.13
Physical interaction between replication protein A (RPA) and MRN: involvement of RPA2 phosphorylation and the N-terminus of RPA1. Biochemistry (2009) 1.07
Ciprofloxacin-induced inhibition of topoisomerase II in human lymphoblastoid cells. Antimicrob Agents Chemother (1991) 0.86
Role of the semi-quinone free radical of the anti-tumour agent etoposide (VP-16-213) in the inactivation of single- and double-stranded phi X174 DNA. Br J Cancer (1990) 0.86
Autocrine motility factor/phosphoglucose isomerase regulates ER stress and cell death through control of ER calcium release. Cell Death Differ (2011) 0.85
Selective induction of apoptosis in Hep 3B cells by topoisomerase I inhibitors: evidence for a protease-dependent pathway that does not activate cysteine protease P32. J Clin Invest (1996) 0.83
Overexpression of the anti-apoptotic caspase-2 short isoform in macrophage-derived foam cells of human atherosclerotic plaques. Am J Pathol (2003) 0.83
Development of a high-content screen for the identification of inhibitors directed against the early steps of the cytomegalovirus infectious cycle. Antiviral Res (2014) 0.83
DNA repair in Etoposide-induced DNA damage in lymphocytes of breast cancer patients and healthy women. Int J Clin Exp Med (2009) 0.80
ATM-mediated KDM2A phosphorylation is required for the DNA damage repair. Oncogene (2015) 0.79
Structure-activity relationships of VP-16 analogues. Cancer Chemother Pharmacol (1994) 0.78
Identification and Validation of Small Molecules That Enhance Recombinant Adeno-associated Virus Transduction following High-Throughput Screens. J Virol (2016) 0.76
Glucose-dependent anaplerosis in cancer cells is required for cellular redox balance in the absence of glutamine. Sci Rep (2016) 0.75
Purification of a new peroxidase catalysing the formation of lignan-type compounds. Biochem J (1991) 0.75
The effect of etoposide on human CFU-GM. Br J Cancer (1985) 0.75
Effect of Heat-Inactivated Clostridium sporogenes and Its Conditioned Media on 3-Dimensional Colorectal Cancer Cell Models. Sci Rep (2015) 0.75
Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol (2001) 4.73
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol (2000) 3.38
Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme. J Biol Chem (1987) 1.66
Inhibition of p34cdc2 kinase activity by etoposide or irradiation as a mechanism of G2 arrest in Chinese hamster ovary cells. Cancer Res (1990) 1.49
Proliferation dependence of topoisomerase II mediated drug action. Biochemistry (1986) 1.37
DNA double-stranded breaks in mammalian cells after exposure to intercalating agents. Biochim Biophys Acta (1981) 1.34
Qualitative and quantitative aspects of intercalator-induced DNA strand breaks. Biochim Biophys Acta (1979) 1.34
DNA topoisomerases as targets for cancer therapy. Biochem Pharmacol (1985) 1.15
Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res (1988) 1.13
Protein-associated DNA breaks in cells treated with adriamycin or ellipticine. Biochim Biophys Acta (1978) 1.13
Kinetics of formation and disappearance of a DNA cross-linking effect in mouse leukemia L1210 cells treated with cis- and trans-diamminedichloroplatinum(II). Cancer Res (1978) 1.11
Topoisomerase-specific drug sensitivity in relation to cell cycle progression. Mol Cell Biol (1987) 1.09
UP element-dependent transcription at the Escherichia coli rrnB P1 promoter: positional requirements and role of the RNA polymerase alpha subunit linker. Nucleic Acids Res (2001) 1.08
Differences between melphalan and nitrogen mustard in the formation and removal of DNA cross-links. Cancer Res (1978) 1.04
Purification and characterization of an altered topoisomerase II from a drug-resistant Chinese hamster ovary cell line. Biochemistry (1989) 1.02
DNA binding by epipodophyllotoxins and N-acyl anthracyclines: implications for mechanism of topoisomerase II inhibition. Mol Pharmacol (1988) 0.99
Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice. Cancer Res (1990) 0.98
Possible role for p34cdc2 kinase in etoposide-induced cell death of Chinese hamster ovary cells. Cancer Res (1990) 0.98
Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study. Cancer (1983) 0.97
DNA topoisomerase II: a primer on the enzyme and its unique role as a multidrug target in cancer chemotherapy. Pharmacol Ther (1987) 0.95
Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells. Cancer Res (1987) 0.95
Comparison of microsomal drug hydroxylation in lung and liver of various species. Res Commun Chem Pathol Pharmacol (1970) 0.94
Potentiation of etoposide-induced DNA damage by calcium antagonists in L1210 cells in vitro. Cancer Res (1984) 0.94
Lung cancer in patients < 50 years of age: the experience of an academic multidisciplinary program. Chest (1999) 0.92
Verapamil-induced augmentation of etoposide accumulation in L1210 cells in vitro. Cancer Res (1985) 0.91
Depletion of topoisomerase II in isolated nuclei during a glucose-regulated stress response. Mol Cell Biol (1989) 0.88
A pilot investigation of the psychologic functioning of patients with anticipatory vomiting. Cancer (1982) 0.88
Potentiation of bleomycin toxicity by oxygen. Cancer Treat Rep (1982) 0.87
DNA topoisomerases in cancer therapy. Anticancer Drug Des (1987) 0.85
Characterization of VP-16-induced DNA damage in isolated nuclei from L1210 cells. Biochim Biophys Acta (1984) 0.85
Effects of verapamil on etoposide, vincristine, and adriamycin activity in normal human bone marrow granulocyte-macrophage progenitors and in human K562 leukemia cells in vitro. Cancer Res (1985) 0.84
Repair of deoxyribonucleic acid lesions caused by adriamycin and ellipticine. Biochem Pharmacol (1982) 0.82
Relationship between cytotoxicity and DNA strand breakage produced by adriamycin and other intercalating agents. Int J Radiat Oncol Biol Phys (1979) 0.82
A method for assessing damage to mitochondrial DNA caused by radiation and epichlorohydrin. Mol Pharmacol (1985) 0.82
Paraquat-induced DNA damage in mammalian cells. Biochem Biophys Res Commun (1979) 0.81
Glycogen-containing neuroblastoma with clinical and histopathologic features of Ewing's sarcoma. Cancer (1978) 0.81
Inhibition of topoisomerases by fredericamycin A. Cancer Chemother Pharmacol (1989) 0.81
Dissociation of cytotoxicity and DNA cleavage activity induced by topoisomerase II-reactive intercalating agents in hamster-human somatic cell hybrids. Cancer Chemother Pharmacol (1992) 0.80
Role of proliferation in determining sensitivity to topoisomerase II-active chemotherapy agents. NCI Monogr (1987) 0.79
Abrogation of etoposide-mediated cytotoxicity by cycloheximide. Biochem Pharmacol (1988) 0.79
Unconventional cancer therapy. Compr Ther (1985) 0.79
Inhibition of etoposide-induced DNA damage and cytotoxicity in L1210 cells by dehydrogenase inhibitors and other agents. Cancer Res (1984) 0.79
Altered function of DNA topoisomerases as a basis for antineoplastic drug action. Important Adv Oncol (1988) 0.79
Mediation of multi-drug resistance in a Chinese hamster ovary cell line by a mutant type II topoisomerase. NCI Monogr (1987) 0.78
Relationship between DNA damage and survival in formaldehyde-treated mouse cells. Mutat Res (1980) 0.78
Prospective hemostatic studies in a patient having paroxysmal nocturnal hemoglobinuria, pregnancy, and cerebral venous thrombosis. Am J Obstet Gynecol (1982) 0.77
Neurotoxicity of antineoplastic agents. Crit Rev Oncol Hematol (1993) 0.77
Sex-dependent effects of cyclic AMP on the hepatic mixed function oxidase system. Res Commun Chem Pathol Pharmacol (1973) 0.77
Isolation and purification of large quantities of DNA replication intermediates by pH step alkaline elution. Chromosoma (1979) 0.76
Etoposide-induced DNA cleavage in human leukemia cells. Cancer Chemother Pharmacol (1987) 0.76
Comparison of DNA damage by methylmelamines and formaldehyde. J Natl Cancer Inst (1981) 0.75
A study of drug-induced kinetic perturbations in the marrow of a patient with neuroblastoma. Cancer (1980) 0.75
Properties of a purified nuclear topoisomerase from L1210 cells. Biochim Biophys Acta (1983) 0.75
Impact of managed care on one training program. University of Florida at Gainesville. Arch Surg (1995) 0.75
The effects of dibutyryl cyclic AMP on the hepatic mixed function oxidase system in hormonally altered rats. Res Commun Chem Pathol Pharmacol (1973) 0.75
Cytotoxicity and deoxyribonucleic acid damage associated with bromoacetate. Biochem Pharmacol (1981) 0.75
Beyond kinetics: the study of DNA damage and repair in bone marrow cells. Exp Hematol (1979) 0.75
A phase II study of weekly alternating chemotherapy in extensive-stage small cell lung cancer. Cancer Invest (2001) 0.75
Probenecid inhibition of methotrexate cytotoxicity in mouse L1210 leukemia cells. Cancer Treat Rep (1984) 0.75
Changing prognoses in selected cancers. Med Sect Proc (1985) 0.75
Anticoagulation therapy for radiation-induced myelopathy. Ann Pharmacother (2001) 0.75
Phase I trial of concurrent thoracic radiation and continuous infusion cisplatin and etoposide in stage III non-small cell lung cancer. Lung Cancer (1999) 0.75
Planning for discovery. J Fla Med Assoc (1992) 0.75
Resistance to inhibitors of DNA topoisomerases. Cancer Treat Res (1991) 0.75
Comparative molecular field analysis of in vitro growth inhibition of L1210 and HCT-8 cells by some pyrazoloacridines. J Med Chem (1993) 0.75
Medical schools on the fault line. J Fla Med Assoc (1994) 0.75
A phase II study of mitomycin C, etoposide, and cisplatin in advanced non-small cell lung cancer. Cancer Invest (2000) 0.75
Allergic reaction to cyclophosphamide in a mechlorethamine-sensitive patient. Cancer Treat Rep (1977) 0.75
Effects of serum-fractions from patients with Eaton-Lambert syndrome on rat cortical synaptosomal [3H]acetylcholine release. Biochem Pharmacol (1986) 0.75